Methods:
Using the 2016–2017 Sunshine Act Open Payments database, general payments made to psychiatrists were descriptively analyzed. The number of psychiatrists who received payments, and median number, value (in US dollar), and nature of payments to psychiatrists were quantified. Top 10 manufacturers who paid the most to psychiatrists were also reported.

Results:
Over half of active psychiatrists (55.7%) received some form of payments from pharmaceutical manufacturers. Of these, top 2.8% of psychiatrists received 82.6% of the payments. Pharmaceutical manufacturers provided 812,877 payments worth $110,512,607.18 to 26,422 psychiatrists in the US. Compensation for services (e.g., speaker’s bureaus) and consulting fees altogether constituted 71.4% of the total payment, with a median value of $1,725.00 and $700, respectively. Among all psychiatrists who received payments, manufacturers that paid the most included Otsuka Pharmaceuticals, Alkermes, and Sunovion Pharmaceuticals.

Conclusions:
The PPSA was created to foster transparent disclosure of any financial relationship between physicians and industry. Findings highlight that many active psychiatrists receive payments from pharmaceutical industry and payment forms were varied (e.g., food/beverage, educational materials, and compensation for services).

Jan 13, 2024 10:18:32pm

Το ξέρετε ό,τι πολλοί *γιατροί τα πέρνουν για να προωθούν τα συμφέροντα των φαρμακοβιομηχανιών; 500εύρα τη φορά!

Jan 13, 2024 10:15:52pm

Ο λόγος που δεν τα σταματάνε οι *γιατροί, είναι να βγάλουν και κανά ευρώ οι φαρμακοβιομηχανίες.

Jan 13, 2024 10:12:29pm

Solon Papageorgiou shared a link.

https://www.youtube.com/@ITNArchive